| Cutaneous melanoma is a malignant skin cancer with a poor prognosis. However, recent advances in immune checkpoint blockade and targeted therapy have significantly improved outcomes in advanced-stage resectable melanoma，which have made neoadjuvant therapy a viable option for melanoma patients. Currently, several relevant clinical trials on neoadjuvant therapy have achieved significant results. Therefore, in this review, we focused on the selection of neoadjuvant therapy, subsequent surgical considerations after neoadjuvant therapy, prognostic indicators, and baseline biomarkers, aiming to provide to provide new strategies for the treatment of cutaneous melanoma. |
